Острый цистит в практике акушера-гинеколога

В. А. Каптильный

doi:10.21518/2079-701X-2018-13-114-123

Острый цистит в практике акушера-гинеколога

В. А. Каптильный

https://doi.org/10.21518/2079-701X-2018-13-114-123

Полный текст:

PDF (Rus)

Аннотация

В обзоре литературы рассматриваются современные данные о диагностике и лечении острого цистита. Освещены вопросы эпидемиологии и этиологии острого цистита. Приводятся основные и альтернативные схемы лечения острого цистита с позиции доказательной медицины.

Ключевые слова

инфекция мочевыводящих путей, цистит, Фосфомицин

Об авторе

В. А. Каптильный

Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)
Россия
к.м.н., доцент кафедры акушерства и гинекологии № 1 лечебного факультета

Список литературы

1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am, 2014, 28: 1.

2. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat, 2011, 13: 1.

3. Каптильный В.А. Инфекция мочевыводящих путей во время беременности. Архив акушерства и гинекологии им. В.Ф. Снегирева, 2015, 2(4): 10-19.

4. Бахарева И.В. Инфекции мочевыводящих путей у беременных: профилактика и лечение. Акушерство и гинекология, 2018, 3: 129- 137.

5. Каптильный В.А. Течение и исходы беременности у пациенток с бессимптомной бактериурией: автореферат дис. ... к.м.н. М., 2008. 25 с.

6. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis, 2007, 45: 273.

7. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012, 366: 1028.

8. Gupta K, Trautner B. In the clinic. Urinary tract infection. Ann Intern Med, 2012, 156: ITC3.

9. Walker E, Lyman A, Gupta K et al. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis, 2016, 63: 960.

10. Linsenmeyer K, Strymish J, Gupta K. Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections. Antimicrob Agents Chemother, 2015, 59: 7593.

11. Naber KG, Schito G, Botto H et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol, 2008, 54: 1164.

12. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 2011, 52: e103.

13. Swami SK, Liesinger JT, Shah N et al. Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clin Proc, 2012, 87: 753.

14. Talan DA, Krishnadasan A, Abrahamian FM et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinoloneresistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis, 2008, 47: 1150.

15. Gupta K, Hooton TM, Miller L. Uncomplicated UTI IDSA Guideline Committee. Managing uncomplicated urinary tract infection–making sense out of resistance data. Clin Infect Dis, 2011, 53: 1041.

16. Olson RP, Harrell LJ, Kaye KS. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob Agents Chemother, 2009, 53: 1285.

17. Ho PL, Yip KS, Chow KH et al. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis, 2010, 66: 87.

18. Lautenbach E. Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin Infect Dis, 2013, 57: 1266.

19. Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA, 2014, 311: 844.

20. Juthani-Mehta M, Quagliarello V, Perrelli E et al. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc, 2009, 57: 963.

21. Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract, 2011, 12: 36.

22. Sundvall PD, Elm M, Ulleryd P et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr, 2014, 14: 88.

23. Dasgupta M, Brymer C, Elsayed S. Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study. Arch Gerontol Geriatr, 2017, 72: 127.

24. Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. J Am Med Dir Assoc, 2014, 15: 133.

25. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med, 2013, 369: 1883.

26. Coyne KS, Sexton CC, Vats V et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology, 2011, 77: 1081.

27. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med, 2007, 167: 2207.

28. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc, 2011, 86: 480.

29. Huttner A, Verhaegh EM, Harbarth S et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015, 70: 2456.

30. Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. CMAJ, 2015, 187: 648.

31. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 2015, 63: 2227.

32. Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc, 2016, 64: 798.

33. Falagas ME, Vouloumanou EK, Togias AG et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother, 2010, 65: 1862.

34. Huttner A, Kowalczyk A, Turjeman A et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial. JAMA, 2018, doi: 10.1001/jama.2018.3627.

35. Datta R, Juthani-Mehta M. Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis. JAMA, 2018, 319: 1771.

36. Rodríguez-Baño J, Alcalá JC, Cisneros JM et al. Community infections caused by extendedspectrum beta-lactamase-producing Escherichia coli. Arch Intern Med, 2008, 168: 1897.

37. Zalmanovici Trestioreanu A, Green H, Paul M et al. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev, 2010: CD007182.

38. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections, warns about disabling side effects that can occur together. http: //www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 26, 2016).

39. Little P, Moore MV, Turner S et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ, 2010, 340: 199.

40. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open, 2013, 3: e004152.

41. Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother, 2014, 69: 769

42. Gágyor I, Bleidorn J, Kochen MM et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 2015, 351: h6544.

43. Kronenberg A, Bütikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ, 2017, 359: j4784.

44. Klimberg I, Shockey G, Ellison H et al. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr Med Res Opin, 2005, 21: 1241.